Catalyst Pharmaceutical CPRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $63.73M+12.3% | $52.7M-5.8% | $52.78M+20.3% | $52.11M+27.7% | $56.74M+144% | ||
| $70K-39.1% | $72K-36.8% | $72K-32.1% | $116K+27.5% | $115K+33.7% | ||
| $6.26M+7.0% | $5.66M+9.5% | $5.67M+28.2% | $7.6M+72.3% | $5.85M-29.1% | ||
| $2.34M+0.6% | $4.51M— | —— | $2.43M+50.9% | $2.32M+32.9% | ||
| $4.36M-24.7% | $20.07M+178% | $40.55M+3,606% | $0— | $5.79M-17.1% | ||
| -$2.24M-1,043% | $9.22M— | $9.09M+354% | -$455K— | $237K-94.5% | ||
| -$4.05M+24.9% | —— | —— | -$5.67M-80.3% | -$5.4M-19.0% | ||
| -$9.21M-261% | $5.21M-41.5% | $13.24M-33.9% | $8.27M-49.7% | -$2.55M-130% | ||
| -$2.45M+65.1% | —— | $6.7M— | $7.41M-24.5% | -$7.02M-680% | ||
| $9.7M+3.8% | $9.47M+1.3% | $9.34M0.0% | $9.34M0.0% | $9.35M0.0% | ||
| $4.75M+79.7% | $3.37M-49.9% | -$2.09M-219% | -$2.95M-30.5% | $2.64M+331% | ||
| -$106K-9.3% | -$102K-8.5% | -$102K-8.5% | -$100K-8.7% | -$97K-9.0% | ||
| $59.59M-0.8% | $44.89M-36.7% | $32.44M-55.5% | $71.3M+11.2% | $60.04M+88.1% | ||
| $27K— | $32K-63.6% | $0-100% | $26K+160% | $0-100% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$27K— | -$32K+63.6% | $0+100% | -$26K-160% | -$0+100% | ||
| $14.57M+130% | $6.33M— | $6.33M— | $6.33M— | $6.33M— | ||
| $3.3M— | $0— | $0— | $0— | $0-100% | ||
| $301K-53.1% | $912K+96.6% | $0— | $219K— | $642K+215% | ||
| -$12.87M-521% | -$25.58M-677% | $4.65M— | $872K-24.6% | $3.06M-97.8% | ||
| $46.69M-26.0% | $19.28M-74.4% | $37.09M-44.3% | $72.14M+10.5% | $63.1M-63.5% | ||
| $140K+35.9% | $130K+38.3% | $121K-89.6% | $112K+49.3% | $103K+58.5% | ||
| $1.84M+188% | $16.85M+0.5% | $15.9M-9.6% | $38.6M— | $639K— | ||
| $135K+125% | $116K+197% | $96K-91.1% | $78K+158% | $60K+139% | ||
| $9.7M+3.8% | $9.47M+1.3% | $9.34M0.0% | $9.34M0.0% | $9.35M0.0% | ||
| $70K-39.1% | $72K-36.8% | $72K-32.1% | $116K+27.5% | $115K+33.7% | ||
| $4.75M+79.7% | $3.37M-49.9% | -$2.09M-219% | -$2.95M-30.5% | $2.64M+331% | ||
| -$9.21M-261% | $5.21M-41.5% | $13.24M-33.9% | $8.27M-49.7% | -$2.55M-130% | ||
| $2.34M+0.6% | $4.51M— | —— | $2.43M+50.9% | $2.32M+32.9% | ||
| -$106K-9.3% | -$102K-8.5% | -$102K-8.5% | -$100K-8.7% | -$97K-9.0% | ||
| -$2.45M+65.1% | —— | $6.7M— | $7.41M-24.5% | -$7.02M-680% | ||
| $77K+6.9% | $75K+5.6% | $74K+5.7% | $74K+7.2% | $72K+5.9% | ||
| $1.3M+19.7% | $1.24M+14.4% | $1.14M-88.5% | $1.12M+28.0% | $1.09M+11.5% | ||
| —— | $3.13M— | $3.13M— | $3.13M— | $3.13M— | ||
| -$106K-9.3% | -$102K-8.5% | -$102K-8.5% | -$100K-8.7% | -$97K-9.0% | ||
| $59.56M-0.8% | $44.86M-36.6% | $32.44M-55.3% | $71.27M+11.1% | $60.04M+89.3% | ||
| $59.56M-0.8% | $44.86M-36.6% | $32.44M-55.3% | $71.27M+11.1% | $60.04M+89.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Catalyst Pharmaceutical generate?
- Catalyst Pharmaceutical (CPRX) generated $208.2M in operating cash flow over the trailing twelve months.
- What is Catalyst Pharmaceutical's free cash flow?
- After $85.0K of capital expenditures, Catalyst Pharmaceutical's free cash flow was $208.1M over the trailing twelve months, down 22.2% year over year.
- Where does Catalyst Pharmaceutical's cash flow data come from?
- Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
